Inhibitors of Quorum Sensing Receptor LasR

Abstract

Modulation of quorum sensing in Gram-negative bacteria, particularly strains of Pseudomonas which form biofilms, by compounds including those of formula I and formula II: where: AR is optionally substituted phenyl, cycloalkyl or cycloalkenyl or heterocyclic, and R 1 is optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkylthioalkyl or alkyl substituted at the omega position with optionally substituted phenyl, cyclohexyl or cyclohexenyl. In particular compounds inhibit quorum sensing and biofilm formation. Pharmaceutical compositions for treatment of bacterial infections and methods of treatment of such infections are provided

We claim: 
     
         1 . A compound of formula: 
       
         
           
           
               
               
           
         
         where: 
         AR is an optionally substituted phenyl, an optionally substituted cycloalkyl or cycloalkenyl or an optionally substituted heterocyclic group; and 
         R 1  is an optionally substituted straight-chain or branched alkyl group or alkenyl group having 3-18 carbon atoms or is an optionally substituted straight-chain or branched alkyl group having 2-18 carbon atoms wherein one or more non-adjacent —CH 2 — moieties are replaced with —O— or —S—; or 
         R 1  is a C1-C4 alkyl group substituted with an optionally substituted phenyl, cyclohexyl or cyclohexenyl group; 
         with the exception that for compounds of formula I, AR is not an unsubstituted phenyl and wherein optional substitution is substitution with one or more non-hydrogen substituents selected from halogen, hydroxyl, alkoxy, or NH 2 . 
       
     
     
         2 . The compound of  claim 1 , wherein R 1  is a straight-chain or branched alkyl or alkenyl group having 9-12 carbon atoms. 
     
     
         3 . The compound of  claim 1 , wherein R 1  is a straight-chain alkyl or alkenyl group having 9-12 carbon atoms. 
     
     
         4 . The compound of  claim 1 , wherein R 1  is selected from the group consisting of a straight-chain alkyl group having 9-12 carbon atoms, a straight-chain alkenyl group having 9-12 carbon atoms, an alkoxyalkyl group, and an alkylthioalkyl group. 
     
     
         5 . The compound of  claim 1 , wherein AR is selected from the group consisting of substituted phenyl and furyl. 
     
     
         6 . The compound of  claim 1 , wherein AR is a hydroxyl-substituted or a halo-substituted phenyl. 
     
     
         7 . The compound of  claim 1 , wherein AR is an optionally substituted heterocyclic group. 
     
     
         8 . The compound of  claim 1 , wherein AR is furyl. 
     
     
         9 . The compound of  claim 1 , wherein AR is fur-2-yl or fur-3-yl. 
     
     
         10 . The compound of  claim 1 , wherein AR is selected from the group consisting of furyl, thiophenyl, thiazolyl, pyridyl, cyclohexyl and cyclohexenyl, each of which is optionally substituted. 
     
     
         11 . The compound of  claim 1 , wherein AR is cyclohexyl or cyclohexenyl. 
     
     
         12 . The compound of  claim 1  of formula II. 
     
     
         13 . The compound of  claim 12 , wherein AR is selected from the group consisting of phenyl, furyl, thiophenyl, thiazolyl, pyridyl, cyclohexyl and cyclohexenyl, each of which is optionally substituted. 
     
     
         14 . The compound of  claim 12 , wherein R 1  is an optionally substituted straight-chain or branched alkenyl group having 3-18 carbon atoms or is an optionally substituted straight-chain or branched alkyl group having 2-18 carbon atoms or is a C1-C4 alkyl group substituted with an optionally substituted phenyl, cyclohexyl or cyclohexenyl group; 
     
     
         15 . The compound of  claim 12 , wherein R 1  is selected from the group consisting of a straight-chain or branched alkyl group having 9-12 carbon atoms, a straight-chain or branched alkenyl group having 9-12 carbon atoms, an alkoxyalkyl group, and an alkylthioalkyl group. 
     
     
         16 . A compound of any one of formulas: 
       
         
           
           
               
               
           
         
       
     
     
         17 . A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of  claim 1  in combination with a pharmaceutically acceptable carrier. 
     
     
         18 . A method for inhibiting quorum sensing in a Gram-negative bacterium which comprises the step of contacting the Gram-negative bacterium or an environment containing the bacterium with one or more compounds of  claim 1 . 
     
     
         19 . A method for inhibiting biofilm formation by a Gram-negative bacterium which comprises the step of contacting the Gram-negative bacterium, the environment of the bacterium or a biofilm of the bacterium with one or more compounds of  claim 1 . 
     
     
         20 . A method for treating an infection by a Gram-negative bacterium which comprises administering to a subject in need of such treatment a therapeutically effective amount of one or more compounds of  claim 1 .